Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Apogee Therapeutics Inc shares valued at $1,507,657 were sold by HENDERSON MICHAEL THOMAS on Dec 10 ’25. At $75.38 per share, HENDERSON MICHAEL THOMAS sold 20,000 shares. The insider’s holdings dropped to 1,212,987 shares worth approximately $93.82 million following the completion of this transaction.
Also, Dambkowski Carl sold 10,900 shares, netting a total of over 817,500 in proceeds. Following the sale of shares at $75.00 each, the insider now holds 271,108 shares.
Before that, Henderson Jane had sold 1,500 shares from its account. In a trade valued at $112,500, the Chief Financial Officer traded Apogee Therapeutics Inc shares for $75.00 each. Upon closing the transaction, the insider’s holdings decreased to 1,500 shares, worth approximately $15.07 million.
As published in their initiating research note from Stephens on December 17, 2025, Apogee Therapeutics Inc [APGE] has been an Overweight and the price target has been revised to $95. Analysts at Deutsche Bank started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of November 03, 2025, Craig Hallum has initiated its “Buy” rating for APGE. Earlier on October 21, 2025, Mizuho initiated its rating. Their recommendation was “an Outperform” for APGE stock.
Analyzing APGE Stock Performance
On last trading session, Apogee Therapeutics Inc [NASDAQ: APGE] rose 2.45% to $77.35. The stock’s lowest price that day was $74.5366, but it reached a high of $78.135 in the same session. During the last five days, there has been a surge of approximately 1.07%. Over the course of the year, Apogee Therapeutics Inc shares have jumped approximately 63.84%. Shares of the company reached a 52-week high of $78.15 on 12/15/25 and a 52-week low of $26.20 on 04/08/25.
Support And Resistance Levels for Apogee Therapeutics Inc (APGE)
According to the 24-hour chart, there is a support level at 75.21, which, if violated, would cause prices to drop to 73.08. In the upper region, resistance lies at 78.81. The next price resistance is at 80.27. RSI (Relative Strength Index) is 69.66 on the 14-day chart, showing neutral technical sentiment.
Is Apogee Therapeutics Inc subject to short interest?
Stocks of Apogee Therapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by 55782.0 shares to 7.9 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 7.95 million shares. A decline of -0.71% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.26 of the overall float, the days-to-cover ratio (short ratio) decline to 11.26.
Which companies own the most shares of Apogee Therapeutics Inc (APGE)?
In terms of Apogee Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 99 in the next 12 months, up nearly 31.13% from the previous closing price of $75.5. Analysts anticipate Apogee Therapeutics Inc stock to reach 109 by 2025, with the lowest price target being 60. On September 25, 2025, RBC Capital Mkts assigned a price target of “an Outperform” to the stock and initiated coverage with a $60.
